Serum galectin-3 level in systemic sclerosis (Q47866004)

6 February 2018

title

Serum galectin-3 level in systemic sclerosis (English)

1 reference

6 February 2018

author

Nevin Ilhan

5

1 reference

6 February 2018

Suleyman Serdar Koca

1

object named as

Suleyman Serdar Koca

1 reference

6 February 2018

author name string

Fatma Akbas

2

1 reference

6 February 2018

Metin Ozgen

3

1 reference

6 February 2018

Servet Yolbas

4

1 reference

6 February 2018

Baris Gundogdu

6

1 reference

6 February 2018

Ahmet Isik

7

1 reference

6 February 2018

publication date

3 August 2013

1 reference

6 February 2018

published in

Clinical Rheumatology

1 reference

6 February 2018

volume

33

1 reference

6 February 2018

issue

2

1 reference

6 February 2018

page(s)

215-220

1 reference

6 February 2018

https://api.crossref.org/works/10.1007/S10067-013-2346-8

1 reference

Angiogenesis and Vasculopathy in Systemic Sclerosis: Evolving Concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

The regulation of inflammation by galectin-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Oligosaccharide specificity of galectins: a search by frontal affinity chromatography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

The immunological potential of galectin-1 and -3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Role of galectin-3 in human pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Galectin-3 regulates myofibroblast activation and hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Biomarkers in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Biomarkers for skin involvement and fibrotic activity in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Overview of pathogenesis of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Role of galectin-3 in acetaminophen-induced hepatotoxicity and inflammatory mediator production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Galectin 3 and its binding protein in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Serum Levels of Galectin-3: Possible Association with Fibrosis, Aberrant Angiogenesis, and Immune Activation in Patients with Systemic Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Update on indices of disease activity in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

The current state of biomarkers in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10067-013-2346-8

A disease severity scale for systemic sclerosis: development and testing

21 January 2018

1 reference

12 December 2020

Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice

1 reference

12 December 2020

Galectins. Structure and function of a large family of animal lectins

1 reference

12 December 2020

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee

1 reference

12 December 2020

Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity.

1 reference

12 December 2020

Scleroderma (systemic sclerosis): classification, subsets and pathogenesis

1 reference

12 December 2020

Assessment of disease activity.

1 reference

12 December 2020

Measuring disease activity and severity in scleroderma

1 reference

12 December 2020

Role of galectin-3 in leukocyte recruitment in a murine model of lung infection by Streptococcus pneumoniae

1 reference

12 December 2020

Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis

1 reference

12 December 2020

Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies

1 reference

12 December 2020

The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials

1 reference

12 December 2020

10.1007/S10067-013-2346-8

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018